ADRENALINE (EPINEPHRINE)

Brand name:

• Jext® Jnr; Jext®

Form and strength:

Please search for and view the medicine's Public Summary Document (PSD) for more information

Condition/indication:
(therapeutic use)

• Acute allergic reaction with anaphylaxis

Listing requested:

Please see PSD for more information

Funding program:

Please see PSD for more information

Request authority level:

Please see PSD for more information

PBAC submission type:

New PBS listing (Category 4)

Comment:

--

Submission sponsor:

HEALTH TECHNOLOGY ANALYSTS PTY LIMITED

Other PBAC consideration:

--

Submission received for:

July 2024 PBAC meeting

Opportunity for consumer comment:

Open 03/04/2024 and close 29/05/2024 (see PBS Website)

PBAC meeting:

Held on 10/07/2024

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

17/12/2025

Lodgement of required documentation:

02/02/2026

Acceptance of complete documentation:

Accepted

Agreement to listing arrangements:

Commenced on 16/02/2026

Status:

Finalised

7Government processes:

Commenced on 16/03/2026

8Medicine listed on the PBS:

Has not yet occurred

---